b'Source: Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. Hum Vaccin Immunother. 2023 Dec 31;19(1):2193528. doi: 10.1080/21645515.2023.2193528. Epub 2023 Apr 16. PMID: 37062953; PMCID: PMC10114990.Results of the ongoing Phase III trials are expectedLenvatinib, or sunitinib in treatment-nave patients. The toprovideimportantbreakthroughs.Inaddition,results led to the Food and Drug Administration approval there still exists an unmet need for the predictiveof pembrolizumab/lenvatinib for first-line treatment of biomarkers to guide the best initial choice of therapyadult patients with advanced RCC. 2and to optimize the sequential use of available thera- 1Anishchenko K, Antoine S, Geiger C, Lenzmeier R, Kim S, Lloyd peutic agents. The future holds a strong possibility toGL. High-risk Disease and Poor Follow-up: The Importance of Renal witness more immune combinations that hopefullyMass Biopsy in a Cohort of Veterans. Urology. 2022 Sep;167:152-will allow us to achieve long-term remission, and157. doi: 10.1016/j.urology.2022.05.006. Epub 2022 May 16.even cure more patients with metastatic RCC. 2Gebrael G, Sahu KK, Agarwal N, Maughan BL. Update on com-The report in Human Vaccines and Immunotherapeuticsbined immunotherapy for the treatment of advanced renal cell carcinoma. Hum Vaccin Immunother. 2023 Dec 31;19(1):2193528. said those trials include the CLEAR Study, among others.doi: 10.1080/21645515.2023.2193528. Epub 2023 Apr 16. PMID: CLEAR was a three-arm trial involving 1,069 participants37062953; PMCID: PMC10114990.and investigated pembrolizumab/Lenvatinib, everolimus/27'